Lumeblue (previously known as Methylthioninium chloride Cosmo) Եվրոպական Միություն - հունգարերեն - EMA (European Medicines Agency)

lumeblue (previously known as methylthioninium chloride cosmo)

alfasigma s.p.a. - metil-tionin-klorid - colorectal neoplasms; colonoscopy - other diagnostic agents - lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.

Pemazyre Եվրոպական Միություն - հունգարերեն - EMA (European Medicines Agency)

pemazyre

incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - daganatellenes szerek - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed  after at least one prior line of systemic therapy.

Minjuvi Եվրոպական Միություն - հունգարերեն - EMA (European Medicines Agency)

minjuvi

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - daganatellenes szerek - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).

Rybrevant Եվրոպական Միություն - հունգարերեն - EMA (European Medicines Agency)

rybrevant

janssen-cilag international n.v.    - amivantamab - karcinóma, nem kissejtes tüdő - daganatellenes szerek - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Lytgobi Եվրոպական Միություն - հունգարերեն - EMA (European Medicines Agency)

lytgobi

taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - daganatellenes szerek - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.

Yesafili Եվրոպական Միություն - հունգարերեն - EMA (European Medicines Agency)

yesafili

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - szemészeti - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.